HOUSTON, Texas, April 26, 2016 /PRNewswire/ --

The University of Texas MD Anderson Cancer Center has signed a deal with Elekta (EKTA-B.ST) to acquire Elekta Infinity™ linear accelerators, brachytherapy afterloaders as well as software and service.

Bill Yaeger, Elekta's Executive Vice President, Region North America, says: "As a world-renowned cancer center, MD Anderson has been a technology leader in managing the disease. In addition to being one of the first U.S. medical centers to acquire Elekta's new Leksell Gamma Knife® Icon™ brain radiosurgery system, MD Anderson is also part of the consortium to develop the world's first high-field MR-guided linear accelerator. We are proud that it has chosen us again in the expansion of its facilities in Texas. Both organizations share a commitment to quality and the best care possible for patients."

The order, for four Infinity treatment systems, will also include Elekta's high-resolution beam shaping solution, the Agility™ 160-leaf multi-leaf collimator.

The deal also includes four high-dose-rate (HDR) brachytherapy afterloaders and Oncentra^® Brachy treatment planning; MOSAIQ^® Oncology Information System (OIS); Active Breathing Coordinator™ units; as well as service for the hardware and software.

The order will be booked in Elekta's fourth quarter, fiscal year 2015-16.

The above information is such that Elekta AB (publ) shall make public in accordance with the Securities Market Act and/or the Financial Instruments Trading Act. The information was published at 07:30 CET on April 26, 2016.

About Elekta

Elekta is a human care company pioneering significant innovations and clinical solutions for treating cancer and brain disorders. The company develops sophisticated, state-of-the-art tools and treatment planning systems for radiation therapy, radiosurgery and brachytherapy, as well as workflow enhancing software systems across the spectrum of cancer care. Stretching the boundaries of science and technology, providing intelligent and resource-efficient solutions that offer confidence to both health care providers and patients, Elekta aims to improve, prolong and even save patient lives.

Today, Elekta solutions in oncology and neurosurgery are used in over 6,000 hospitals worldwide. Elekta employs around 3,800 employees globally. The corporate headquarters is located in Stockholm, Sweden, and the company is listed on NASDAQ Stockholm. Website: http://www.elekta.com.

For further information, please contact:

Gert van Santen, Group Vice President Corporate Communications, Elekta AB
Tel: +31-653-561-242, e-mail: gert.vansanten@elekta.com
Time zone: CET: Central European Time

Tobias Bülow, Director Financial Communication, Elekta AB
Tel: +46-722-215-017, e-mail: tobias.bulow@elekta.com
Time zone: CET: Central European Time

SOURCE Elekta